Gilad Almogy

Gilad Almogy founded Ultima Genomics in 2016 with a mission to continuously reduce the cost of sequencing to enable the era of data-driven healthcare, transform biology, and improve human health. Before founding Ultima, Gilad had applied deep technology, engineering, and leadership expertise to push technological boundaries and drive transformation across multiple industries.

Gilad was the Founder and CEO of Cogenra Solar, a developer of record breaking shingled solar modules, with more than 7 gigawatts deployed worldwide to date. Gilad led Cogenra from inception until its acquisition by SunPower (NASDAQ: SPWR) in 2015.

Before Cogenra, Gilad was a senior vice president for Applied Materials (NASDAQ: AMAT), the leader in materials engineering solutions used to produce virtually every new semiconductor chip and advanced display in the world. At Applied Materials, Gilad led the Process Diagnostic and Control Group and later the Display Group, a more than $1 billion per year revenue franchise. Gilad joined Applied Materials through its acquisition of Orbot in 1997. While at Orbot and Applied Materials, Gilad led the development of wafer inspection systems that are now widely adopted in semiconductor fabs worldwide.

Gilad earned a PhD in Applied Physics from the California Institute of Technology and a BSc in Mathematics and Physics from the Hebrew University in Jerusalem’s Talpiot program. He is the inventor of more than 80 US Patents.

Location

Palo Alto, United States

Links


Org chart


Teams


Offices

This person is not in any offices


Ultima Genomics

4 followers

Ultima Genomics is unleashing the power of genomics at scale. Their mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology’s complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies.


Employees

11-50

Links